Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Tag Archive for: Nimbus Therapeutics
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases, the companies announced Tuesday.
Pfizer is leveraging its funding and experience with vaccines for meningococcal, flu and RSV to further expand its presence in the field.